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Abstract: Burns and other skin injuries are growing concerns as well as challenges in an era of
antimicrobial resistance. Novel treatment options to improve the prevention and eradication of
infectious skin biofilm-producing pathogens, while enhancing wound healing, are urgently needed
for the timely treatment of infection-prone injuries. Treatment of acute skin injuries requires tailoring
of formulation to assure both proper skin retention and the appropriate release of incorporated
antimicrobials. The challenge remains to formulate antimicrobials with low water solubility, which
often requires carriers as the primary vehicle, followed by a secondary skin-friendly vehicle. We
focused on widely used chlorhexidine formulated in the chitosan-infused nanocarriers, chitosomes,
incorporated into chitosan hydrogel for improved treatment of skin injuries. To prove our hypoth-
esis, lipid nanocarriers and chitosan-comprising nanocarriers (≈250 nm) with membrane-active
antimicrobial chlorhexidine were optimized and incorporated into chitosan hydrogel. The biological
and antibacterial effects of both vesicles and a vesicles-in-hydrogel system were evaluated. The
chitosomes-in-chitosan hydrogel formulation demonstrated promising physical properties and were
proven safe. Additionally, the chitosan-based systems, both chitosomes and chitosan hydrogel,
showed an improved antimicrobial effect against S. aureus and S. epidermidis compared to the formu-
lations without chitosan. The novel formulation could serve as a foundation for infection prevention
and bacterial eradication in acute wounds.
Keywords: chitosan-infused liposomes; chitosan hydrogel; membrane-active antimicrobials; bacterial
eradication; acute wound management; Staphylococcaceae
1. Introduction
Acute skin injuries, such as burns, cuts, or other trauma, are painful breaches of the
skin. With the growing numbers of resistant pathogens, we need to prevent bacterial
infections and treat these breaches timely and efficiently. Larger skin injuries such as burn
trauma cause destruction of the first line of defence, impairing both the physical barrier
and the immune system [1]. These entry points are leaving the patients more vulnerable
to bacterial colonisation and infections [1]. Additionally, it is estimated that as much as
75% of attributable mortality in this patient group is linked to infections, making this the
primary cause of death [2]. Here, skin and soft tissue infections (SSTIs) are the second
leading healthcare-associated class following burn injuries [3] and one of the most common
bacterial infections in the human population [4]. The burns are often prone to biofilm
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formation, increasing the complexity of the wounds and leading to chronicity [5]. The
escalating threat of antimicrobial resistance and biofilm-producing strains influence the
treatment outcome [6]. The incidents of burn injuries are ostensibly decreasing [7]; however,
nearly 9 million injuries globally were related to fire, heat, or hot substances, according to
the Global Burden of Disease 2017 study [8].
In pursuance of novel treatment options for burns and other acute wounds, formula-
tions aiding both microbial eradication and the wound-healing process are highly desirable.
Pharmaceutical technology and nanotechnology could be utilized to increase both these
processes [9]. Herein, the selection of the materials exhibiting intrinsic wound healing, as
well as antimicrobial properties, is fundamental. Chitosan, a natural, cationic polymer,
derived from the deacetylation of chitin [10], has attracted attention as a biomaterial for
wound management [11]. This bioactive polymer, found in marine crustaceans, fungi,
and insects, is regarded both biocompatible and biodegradable [12,13] with confirmed
intrinsic antimicrobial [14] and wound-healing properties [15]. As a result, chitosan has
been utilized in the preparation of various pharmaceutical formulations, ranging from
solid and semi-solid to liquid forms [16]. However, in topical skin therapy, lipid-based
delivery systems, such as liposomes, are often particularly interesting because of their
potential interaction with the skin structure [17] as well as being a solubilizer for substances
with lowered solubility [18]. Moreover, the antimicrobial potential of the lipid-based vesi-
cles, liposomes, can be enhanced by coating of their surface or inclusion of the bioactive
polymers to both improve wound healing and antimicrobial properties [19]. The possi-
bility to infuse liposomes with chitosan forming chitosomes was previously proposed by
our group [20]. These novel vesicles were challenged against vaginal Candida infections
and both chitosomes alone and chitosomes with incorporated metronidazole eradicated
Candida [20]. These chitosomes, unlike many other nanoparticle-based formulations, were
prepared through a rapid one-step method.
Considering the improved antibacterial action, combining chitosomes with membrane
targeting antimicrobials could further increase the antimicrobial capacity through synergic
effects on the bacterial membrane [21]. Chlorhexidine (CHX), a membrane active antimi-
crobial (MAA), is frequently used in the prevention of SSTIs and commonly used in burn
units [22]. The main antibacterial mechanism of CHX is proposed to be destruction of the
bacterial membrane; however, precipitation of the cytoplasm has been observed when
CHX is administered in higher concentrations [23]. Furthermore, topical formulations of
CHX are commonly used in combinational therapy for chronic wounds [24]. Exploiting the
activity of MAAs, such as CHX, in combination with chitosan of higher molecular weight,
affecting the bacterial membrane [25], could prove beneficial in bacterial prevention and
eradication.
Liposomal suspensions are not suitable for direct application onto the skin due to low
viscosity and retention; this limitation is often solved by incorporating the vesicles into
hydrogels [26]. In addition to serving as a vehicle for liposomes, the hydrogel could also
provide an improved release profile and further increase accumulation of the antimicrobial
compound in the wound area [27]. In this study, chitosan was selected as a hydrogel base
due to its bioadhesive and biocompatible properties, which are suitable for pharmaceutical
applications [28,29]. Moreover, we aimed to tailor the release of CHX to assure rapid and
efficient microbial prevention and eradication. Although the hydrogel would swell to a
certain degree in physiological fluids [30], to assure the fast release as well as prolonged
retention on the skin, we combined chitosomes with chitosan hydrogels (Figure 1).
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Figure 1. Illustration of the two types of vesicles utilized in the current study. In the top-half of the illustration, the 
CHX-vesicles (chitosan-free) both as vesicle alone and incorporated in hydrogel network are presented. In the bot-
tom-half of the illustration, the chitosan-infused vesicles, chitosomes, with entrapped CHX are presented both as vesicles 
alone and incorporated in hydrogel. 
In our previous study, we utilized conventional liposomes as primary vesicles for 
CHX further incorporated in chitosan hydrogel for the treatment of chronic wounds. The 
novel formulation assured sustained CHX release [18]. However, that formulation would 
not be optimal for acute wound treatment. To modify the rate of the CHX release to 
achieve faster and efficient antimicrobial action, we propose chitosomes as primary ves-
icles for CHX. Andersen et al. showed an initial burst-release from their chitosomes and 
postulated that this effect might be due to the arrangement of the pharmaceutical com-
pound in the bilayer [31]. In chitosomes, CHX is most likely incorporated within the bi-
layer and associated with the surface of chitosomes, allowing a faster initial release of 
CHX. Additionally, chitosan infused in the vesicles (chitosomes) is surface-available and 
has the possibility of closely interacting with the bacterial membrane immediately (Fig-
ure 1). These two factors could act in synergy, providing a faster onset of the antimicro-
bial action. Since most of the CHX is preserved within the bilayer of chitosomes, it could 
contribute to the long-term effect, similar to what has been previously confirmed for 
conventional CHX liposomes [18]. We hypothesized that combining CHX with chi-
tosan-infused vesicles, chitosomes, could improve microbial eradication, and in a com-
bination with the hydrogel network, serve as a promising platform for the prevention of 
bacterial colonization of acute wounds. 
2. Results and Discussions 
2.1. Vesicle Characteristics 
Chitosan-based formulations could potentially support the wound-healing process 
in all stages of the complex healing cascade [32]. Additionally, hydrogels comprising this 
bioactive polymer could counteract the factors impairing healing processes by an-
ti-inflammatory and antimicrobial actions [33]. Among all biomaterials, chitosan is one of 
the most frequently used ingredients in hydrogel preparation [34,35]; however, other 
formulations are also reported such as nanofibers [36] and nanoparticles [37]. Moreover, 
chitosan is often used as a coating material for vesicles [14]. In this study, we intended to 
Figure 1. Illustration of the two types of vesicles utilized in the current study. In the top-half of the illustration, the
CHX-vesicles (chitosan-free) both as vesicle alone and incorporated in hydrogel network are presented. In the bottom-half
of the illustration, the chitosan-infused vesicles, chitosomes, with entrapped CHX are presented both as vesicles alone and
incorporated in hydrogel.
In our previous study, we utilized conventional liposo es as pri ary vesicles for
CHX further incorporated in chitosan hydrogel for the treatment of chronic wounds.
The novel formulation assured sustained CHX release [18]. However, that formulation
would not be optimal for acute wound treatment. To modify the rate of the CHX release
to achieve faster and efficient antimicrobial action, we propose chitosomes as primary
vesicles for CHX. Andersen et al. showed an initial burst-release from their chitosomes
and postulated that this effect might be due to the arrangement of the pharmaceutical
compound in the bilayer [31]. In chitosomes, CHX is most likely incorporated within the
bilayer and associated with the surface of chitosomes, allowing a faster initial release of
CHX. Additionally, chitosan infused in the vesicles (chitosomes) is surface-available and has
the possibility of closely interacting with the bacterial membrane immediately (Figure 1).
These two factors could act in synergy, providing a faster onset of the antimicrobial action.
Since most of the CHX is preserved within the bilayer of chitosomes, it could contribute
to the long-term effect, similar to what has been previously confirmed for conventional
CHX liposomes [18]. We hypothesized that combining CHX with chitosan-infused vesicles,
chitosomes, could improve microbial eradication, and in a combination with the hydrogel
network, serve as a promising platform for the prevention of bacterial colonization of acute
wounds.
2. Results and Discussions
2.1. Vesicle Characteristics
Chitosan-based formulations could potentially support the wound-healing process
in all stages of th complex healing cascad [32]. Additionally, hydrogels com ising
this bio ctive polymer could countera t the factors impairing ealin processes by ant -
infl mmatory and antimicr bial actions [33]. Among all biomaterials, chitosan is one
of the ost frequently used ingredients in hydrogel preparation [34,35]; however, other
formulations ar also reported such a nanofibers [36] and nanoparticles [37]. More ver,
chitosan is often used as a coating m teri l for ve icles [14]. In this study, we intended to
expl it chit san’s benefici l intri sic properties in both the primary and secondary vehicle
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to maximize the potential treatment outcome. As this formulation is intended for topical
therapy of skin burns and other acute wounds, lipid-based vesicles were selected as the
primary vesicle.
2.1.1. Vesicle Characteristics
The size and zeta potential of vesicles are known to influence the characteristics
of the hydrogel [38] and the treatment outcome. Consequently, we evaluated the size,
zeta potential, CHX entrapment, and pH of the vesicles (Table 1). These properties are
influenced by the method of preparation. The one-pot method generates larger vesicles
with broader size distribution [31]; therefore, probe sonication was utilized to reduce the
vesicle size. The vesicle size was additionally influenced by the incorporation of CHX. A
single sonication cycle was sufficient to reach the intended size. For comparison, to reach
the same vesicle size, the empty vesicles required several sonication cycles. Our targeted
vesicle size was around 200 nm, which was the lower end of the optimal vesicle size range
intended for dermal delivery [39].


















90 ± 4 0.18 ± 0.01 0.6 ± 0.0 - 5.6 ± 0.0




65 ± 16 0.22 ± 0.01 11.5 ± 0.3 - 4.4 ± 0.0




81 ± 6 0.32 ± 0.03 53.6 ± 2.0 68 ± 5 7.0 ± 0.3




69 ± 16 0.30 ± 0.00 79.0 ± 3.7 74 ± 2 5.5 ± 0.1
Results are expressed as means with their respective SD (n = 3). PL-EMP = plain, empty vesicles, CHI-EMP = empty chitosomes,
PL-CHX = plain, CHX-vesicles, CHI-CHX = CHX-chitosomes. 1 Polydispersity index. 2 Entrapment efficiency (%).
The empty vesicles displayed a slightly smaller size; however, these vesicles served
as controls, and the difference would have limited effect on the overall comparison as all
vesicles were loaded into hydrogel networks [38]. To confirm the size and to investigate the
morphology, we utilized transmission electron microscopy (TEM, Figure 2). Both the empty
and CHX-chitosomes were found to be spherical. The size distribution corresponded to the
results obtained with the particle sizer. Considering conventional liposomes, the infusion
of chitosan did not significantly alter the shape of the vesicles.
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The zeta potential of vesicles was highly influenced by both chitosan and CHX
(Table 1). Plain, empty vesicles were, due to the high content of phosphatidylcholine,
exhibiting neutral surface; the addition of chitosan (chitosomes) augmented the zeta po-
tential by almost 11 mV (Table 1), as expected. The incorporation of CHX in plain vesicles
contributed to increased surface charge to 53 mV due to its incorporation within and on the
vesicles (Figure 1). The vesicles comprised of both chitosan and CHX (CHX-chitosomes)
exhibited the highest zeta potential, indicating that chitosan and CHX have synergic effects
on the surface charge. Moreover, these results indicate that both chitosan and CHX are
available on the surface of the vesicles or partially stretches out to the surface from within
the bilayer. The amphipathic nature of CHX would also substantiate this postulation;
however, the substantial increase might suggest that CHX is positioned even further out
within the surface of the chitosan-infused vesicles. The zeta potential of plain, empty
vesicles and empty chitosomes is directly comparable to the results of Andersen et al. [20].
In topical antimicrobial therapy, positively charged vesicles could be beneficial in bacterial
eradication in wounds. Bacterial membranes are slightly negatively charged, whereas
mammalian membranes are closer to neutral [40]; therefore, the potential interaction be-
tween a positively charged formulation and the bacteria could improve both efficacy and
safety [41]. As reported by Ahani and colleagues, where cationic liposomes were proven
beneficial in bacterial eradication [42].
The pH of vesicle suspensions was also influenced by CHX presence; an increased
pH of more than one unit was determined for CHX-formulations as compared with the
corresponding formulation without CHX. Additionally, the effect of acetic acid used in the
production of chitosomes was detected in the pH values.
Due to the interactions between CHX and the vesicles and the increased zeta potential,
we anticipated a relatively high drug entrapment. However, chitosan could potentially
influence the accommodation of CHX within or on the bilayer. High entrapment is impor-
tant in the development of novel antibacterial formulations to ensure sufficient bacterial
eradication and avoid bacteria regrowth. The entrapment efficiencies for both the plain
vesicles and chitosomes were relatively high (Table 1). Remarkably, the entrapment was
not influenced by the inclusion of chitosan in the vehicles. The high entrapment could also
be a result of the interaction between the lipids of the vesicular bilayer and CHX.
2.1.2. Surface-Available Chitosan
The presence of chitosan on the surface of the chitosomes is indicated by the rise
of the zeta potential as compared to the plain vesicles. We sought to compare the initial
chitosan concentration with the amount available on the chitosome surface. In addition,
we investigated whether the concentration of surface-available chitosan would be affected
by the incorporation of CHX within the vesicles. The percentage of surface-available
chitosan is presented in Table 2. As seen in the table, the surface-available chitosan for
chitosomes both with and without CHX was approximately the same. The zeta potential
indicates that CHX was positioned within the bilayer; however, the co-accommodation of
chitosan was not influenced by the presence of CHX. In antimicrobial therapy, the aim is
to preserve chitosan on the surface of the vesicles, allowing chitosan to interact with the
bacteria and cause disturbance to the bacterial membrane, since this is considered crucial
for its antimicrobial effects [25]. Additionally, we wanted to exploit the potential anti-
inflammatory properties of chitosan hydrogel as well as the chitosomes [43]. As indicated
in Table 2, approximately 50% of the initial chitosan concentration was present on the
vesicle surface, as expected considering the molecular size of chitosan. Moreover, chitosan
was accessible to interact with both bacteria and macrophages, therefore improving the
healing.
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Table 2. Surface-available chitosan of the empty and loaded chitosan-infused vesicles.
Surface-Available Chitosan (%) 3
CHI-EMP 50.2 ± 2.9
CHI-CHX 48.5 ± 5.6
Results are expressed as means with their respective SD (n = 3). CHI-EMP = empty chitosomes,
CHI-CHX = CHX-chitosomes. 3 Percentage of initial chitosan concentration (%).
2.1.3. Vesicle Stability
Vesicle stability should be improved upon their incorporation in hydrogel; never-
theless, we evaluated the stability of the vesicle suspensions two and four weeks after
preparation to assure that even suspensions are stable (Table 3). The stability of these
suspensions is influenced by the zeta potential. Two formulations, namely PL-CHX and
CHI-CHX, had a zeta potential above 30 mV, which is expected to stabilize vesicles and
preserve their homogeneity [41]. The vesicle size and zeta potential of CHX-loaded for-
mulations did not change significantly (defining significant over 95%) throughout these
four weeks, as expected, indicating that the repulsing effects of the CHX-chitosomes and
CHX-vesicles are strong enough to stabilize the suspension. However, the empty chito-
somes had a significant increase in zeta potential between the second and fourth week
(p = 0.0005), which would imply that hydrogels are needed to preserve the stability of
drug-free chitosomes. In addition, the empty, plain vesicles also exhibited a significant
change in the zeta potential between preparation and second week (p = 0.009), displaying
less stability of these vesicles with surfaces closer to neutral. The pH of all formulations
was unaffected during the four weeks of the stability evaluation.










































































































Vesicle characteristics evaluated 2 and 4 weeks after preparation. Results are expressed as means with their
respective SD (n = 3). PL-EMP = plain, empty vesicles, CHI-EMP = empty chitosomes, PL-CHX = plain, CHX-
vesicles, CHI-CHX = CHX-chitosomes. 1 Polydispersity index.
2.2. Hydrogel Characterization
2.2.1. Hydrogel Characterization
Texture analysis is an easy method to monitor the hydrogel production, both as an
in-process control as well as a method to determine the effects of modifications in the
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hydrogel composition [44]. Moreover, it can be utilized for the monitoring of long-term
hydrogel stability [45]. Considering the use of hydrogels as skin formulations, this method
has been utilized to assess the user-friendliness of both conventional and physical chitosan
hydrogels [45,46]. We aimed to utilize the procedure as an in-process control and examine
the texture properties upon incorporation of the different vesicles into the original chitosan
network. This analysis generates the hardness, cohesiveness, and adhesiveness as quality
attributes of the hydrogels. The hardness is expressed as the maximum force required for
compressing the hydrogel. The cohesiveness is the level of deformation to the hydrogel
upon compression, whereas the adhesiveness describes the hydrogel’s adhesion to the
probe compressed into the hydrogel [44]. All parameters for all five hydrogel formulations
are presented in Figure 3.
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Figure 3. Texture properties of the different chitosan hydrogel formulations All results are expressed
as means with their respective SD (n = 3). Hydrogel = plain hydrogel, HG-PL-EMP = plain, empty
vesicles-in-hydrogel, HG-C I-EMP = empty chitosomes-in-hydrogel, HG-PL-CHX = plain, CHX-
vesicles-in-hydrogel, HG-C I-CHX = CHX-chitosomes-in-hydrogel. * p < 0.05.
e ar ess f t e r els i c r rati e t esicles, t lai esicles a
chitoso es, increased compared to the plain (vesicle free) chitosan hydrogel. This increased
hardness is in accordance with the findings by Jøraholmen et al. [45]; however, the slight
increase in the mean hardness of the CHX-vesicles-containing hydrogels is not significant
compared to the plain hydrogel or the hydrogels without CHX. The cohesiveness of the
plain chitosan hydrogel was significantly higher than all other formulations (Figure 3).
These findings are deviating from our previously reported results on conventional lipo-
somes incorporated in hydrogel. However, the adhesiveness data were in agreement with
our previous findings [18]. Moreover, we used texture analysis to determine the stability of
the hydrogel formulations; all hydrogels proved to remain relatively stable over a period
of four weeks (Table S1).
Considering the pH measurements, no larger variations between the different hydro-
gels were observed. The values were ranging between the plain hydrogel, with the lowest
pH at 4.6, to HG-PL-EMP, displaying the highest pH of 4.9. The rest of the hydrogels had
a pH of 4.7. Normal, intact human skin has a pH between 4 and 6 [47], while wounds
often display a more alkaline environment [48]. It was suggested that wound healing is
improved under more acidic conditions [49], and that the optimal growth conditions of
many common skin pathogens are closer to neutral [48]. Therefore, restoring the acidic
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wound environment would be considered advantageous. Our hydrogels would clearly
restore the acidic environment and potentially enhance the healing process. Nevertheless,
it is important to state that an acidic pH of skin dressings alone is not sufficient to maintain
proper healing cascades [50]. Therefore, we utilized chitosan and CHX to enhance the
antimicrobial and anti-inflammatory properties.
2.2.2. Viscosity Evaluation
In addition to the texture analysis, we sought to investigate the rheological behavior
of the plain hydrogel and hydrogels comprising CHX-vesicles. The rheological behavior
could elucidate the applicability and therefore the user-friendliness of semi-solid formu-
lations [51]. These properties could be influenced by the temperature. Consequently, we
evaluated the hydrogels at 25 ◦C (Figure 4a,b) and 32 ◦C (Figure 4c,d), corresponding
to dermal application. As seen in Figure 4, the shear stress increased (Figure 4a,c) and
viscosity decreased (Figure 4b,d) with increasing shear rate. All hydrogels demonstrated
pseudoplastic flow with shear thinning behavior. The rheological behavior was seemingly
not influenced by the incorporation of CHX-chitosomes or plain vesicles with CHX. We
did not observe any differences in viscosity between different hydrogels as we did for
the cohesiveness determined in the texture analysis. Kaplan and colleagues incorporated
liposomes in chitosan hydrogel and observed decreased viscosity upon the incorporation
of liposomes [52]. However, in their study, the chitosan concentration was significantly
lower than in our study. Phospholipids are known to act as plasticizers [53]; therefore, they
could increase the mobility within the hydrogel network, leading to a decreased viscosity.
Yet, this was not observed in our study. The rheological behavior of vesicles-in-hydrogel is
highly influenced by the composition of carriers, lipid concentration, type of polymer, and
polymer concentration [54].
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Contrary to the effect of incorporation of vesicles into the hydrogel network, the
temperature affected the rheological behavior of all hydrogels. The same trends observed at
25 ◦C were observed at 32 ◦C as well; however, shear stress and viscosity were significantly
lowered at 32 ◦C. In pharmaceutical formulations, both the shear thinning behavior and
the lowered viscosity at application-site temperature (32 ◦C for skin) could improve the
user-friendliness upon administration [51].
2.3. CHX Release
Topical, localized treatment of burn injuries and acute wounds is preferred, as this
provides sufficient concentration of the antimicrobial compound in the infected area [55].
Consequently, patients could avoid both bacterial regrowth and unnecessary adverse sys-
temic effects. We compared the CHX release and permeation from formulated CHX, both
the vesicles and vesicles-in-hydrogel, to CHX dissolved in the acceptor medium (Figure 5).
As anticipated, the dissolved CHX permeated faster than CHX from all other formulations.
Only the CHX-chitosomes released a significantly greater amount than both vesicles-in-
hydrogel formulations under the tested conditions. The CHX-chitosomes seemingly had a
higher mean release than the plain vesicles with CHX. This might be due to the compe-
tition between CHX and chitosan within the lipid bilayer of the vesicles, as CHX might
be expelled. Interestingly, comparing the vesicles-in-hydrogel, the CHX release from the
formulation comprising chitosomes displayed sustained release; however, it was not signifi-
cantly relevant. We postulate that this effect might be due to the effect of the positive charge
of the surrounding chitosan hydrogel network. The zeta potential of CHX-chitosomes was
significantly higher than the zeta potential of plain vesicles with CHX (Table 1), which
might lead to stronger repulsion between the hydrogel and the CHX-chitosomes. This sim-
ilar effect has previously been demonstrated by Hurler and colleagues [38]. This repulsive
effect could also stabilize the vesicles incorporated in the hydrogel network. However,
the effect of the wound exudate should not be neglected [18]. Moreover, in an in vivo
challenge, the hydrogel would be exposed to wound bed comprising exudates and blood
components resulting in its swelling [30].
Vesicles-in-hydrogels often offer a prolonged drug release profile, important for
chronic wound treatment [56].
2.4. Evaluation of Potential Toxicity
The biocompatibility of any formulation intended for burns and other wounds is
essential for a successful treatment outcome. Reduced cell compatibility could prevent
or delay the intricate healing cascade. After skin disruption, keratinocytes migrate and
proliferate to close the wound area and are, together with fibroblasts, fundamental in
the healing process [57]. Therefore, cell toxicity studies were performed for both vesicles
(Figure 6) and hydrogels (Figure 7) after 24 h exposure of each formulation to keratinocytes.
The treated cells were compared with non-treated cells to assess the safety and com-
patibility of each formulation. As seen in Figure 6, the vesicles did not impair the cell
survival, regardless of their concentration. Additionally, the highest lipid concentration
(50 µg/mL) of chitosomes exhibited a significantly improved cell proliferation as com-
pared to the cells treated with only medium (control). Both empty chitosomes (p = 0.02)
and CHX-chitosomes (p = 0.01) improved cell survival in the highest lipid concentration.
The improved proliferation of keratinocytes exposed to chitosan can be attributed to its
positive effects on cell growth. The vesicles and chitosomes with CHX appeared to display
a concentration-dependent trend with improved cell viability in the highest concentra-
tions. Other chitosan-comprising formulations such as chitosan-coated liposomes have
been evaluated in various cell lines. Mengoni and colleagues demonstrated compatible
chitosan-coated liposomes in keratinocytes (HaCaT cells) [58]. Phetdee and colleagues
investigated the proliferation in HaCaT cells treated with chitosan-coated liposomes and
reported no negative proliferative effects [59]. Additionally, proliferative effects have been
reported in fibroblasts treated with chitosan [60]. On the other hand, CHX has been shown
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to demonstrate toxicity in both fibroblasts [61] and keratinocytes [62]; however, we did not
detect any toxicity issues with CHX-chitosomes (Figure 6).
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Figure 5. CHX release and permeation from formulated and free CHX after 24 h utilizing the
Franz diffusion system (32 ◦C). The release is presented as the percentage of the initial con-
centration and all formulations were adjusted to the same initial concentration. All results
are expressed as means with their respective SD (n = 3). CHX = dissolved CHX, PL-CHX =
plain, CHX-vesicles, CHI-CHX = CHX-chitosomes, HG-PL-CHX = plain, CHX-vesicles in hydrogel,
HG-CHI-CHX = CHX-chitosomes in hydrogel. * p < 0.05.
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Figure 6. Evaluation of vesicles cell toxicity in HaCaT cells. Three different concentrations were
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PL-CHX = plain, CHX-vesicles, CHI-CHX = CHX-chitosomes.
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chitosomes-in-hydrogel.
In addition to the evaluation of the vesicles compatibility, we investigated the cell
compatibility of hydrogels (Figure 7). The hydrogels did not exhibit any toxicity toward the
keratinocytes; however, non of the hydrogels significantly improved cell survival. The cell
compatibility of hydrogels or other wound dressing materials has previously been r ported
in both keratinocytes and fibroblasts [63–65]. Additionally, Hurler and colleagues demon-
strated in a murine burn model that liposomes-in-hydrogel formulations with mupirocin
were safe [66]. Chitosan is generally regarded as both safe and biocompatible [12]. How-
ever, the degree of deacetyl ti n and chitosan co centration play an important role in cell
compatibility. Due to the complex process of wound healing, the full extent of the underly-
ing mechanisms responsible for the effects of chitosan on keratinocytes or fibroblasts are
not fully elucidated [60,67]. However, chitosan appears to support granulation and remod-
eling through its effects on the inflammatory cells and growt factors [68]. Certain rowth
factors are important in the migration and proliferation of k ratin cytes [69]. Consequently,
the effects of chitosan-based formulations on inflammatory cells are important to monitor.
In the inflammation phase, immune cells are requited to the wound bed, and some
cells differentiate into macrophages. These cells initiate a process that coordinates other
cells in the overlapping phases in the healing process as well as combats microorganisms
in the injured area [70]. The involvement of macrophages in the wound-healing cascade
is extensive and not fully elucidated [71]. We have previously confirmed a decreased
inflammatory activity in cells treated with chitosan formulations [18]. The CHX-chitosomes
have not been evaluated for their potential effect on macrophages earlier. Figure S1
indicates that chitosan-infused vesicles did not potentiate immune response. Interestingly,
the plain vesicles demonstrated a dose-dependent reduction of the inflammatory response
in lipopolysaccharide (LPS)-induced murine macrophages compared to untreated activated
cells. These results are promising considering application in wound therapy.
In the wound-healing process, both cell compatibility and inflammatory responses are
important factors. Additionally, the ability of cells to migrate into the wound bed to close
the wound area is equally important for the wound-healing process. The impact of chitosan
on the migratory abilities of different cell lines was previously evaluated [35], and the re-
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sults are encouraging for our system. Formulations containing chitosan have demonstrated
improved cell migration in fibroblasts [72], macrophages [73], and keratinocytes [74].
2.5. Antimicrobial Evaluation
Tailoring drug delivery systems comprising chitosan to optimize its intrinsic antimi-
crobial activity could improve the effect of the formulation itself [14]. Chitosan is known
to act against Staphylococcus aureus, which is one of the most common skin pathogens [75]
as previously reported [76,77]. Although the mechanisms of the antimicrobial activity of
chitosan are not fully elucidated, the electrostatic interaction between the slightly nega-
tively charged bacterial membrane and the positively charged chitosan groups is the most
common explanation [76]. In addition, reports suggest that chitosan, especially higher
molecular weight chitosan, could form an envelope around the bacteria, depriving them
of nutrients and closing of the exchange with the surrounding environment [78]. These
strong effects on the bacteria could act in synergy with MAAs such as CHX. Therefore,
we sought to compare plain vesicles and chitosomes both with and without CHX to as-
sess the potential antimicrobial effects. Through the modified broth dilution method, we
demonstrated a lowered minimum bactericidal concentration (MBC) in both S. aureus and
Staphylococcus epidermidis cultures from formulations comprising both CHX and chitosan
compared to their respective controls (Table 4). Chitosomes without CHX and CHX-vesicles
displayed improved activity compared to the plain, empty vesicles. As expected, plain,
empty vesicles did not eradicate a sufficient number of bacteria to reach MBC, neither with
S. aureus nor S. epidermidis. However, in the highest concentration, the plain-empty vesicles
reduced the S. epidermidis colony count by approximately 50%. The antimicrobial activity
of CHX-chitosomes against both bacteria was proven to be superior to the other vesicles,
indicating that there is a synergetic effect between CHX, our model MAA, and chitosan, as
hypothesized.









All results are expressed as the lipid concentration upon reaching MBC (n = 3). PL-EMP = plain, empty vesicles,
CHI-EMP = empty chitosomes, PL-CHX = plain, CHX-vesicles, CHI-CHX = CHX-chitosomes.
Alshamsan and colleagues evaluated the antibacterial efficacy of chitosan-coated
and non-coated liposomes loaded with dicloxacillin against methicillin-resistant S. aureus.
Dicloxacillin, commonly used in skin infections, demonstrated improved activity of non-
coated liposomes; however, the activity of coated liposomes was retained compared to
dicloxacillin in solution [79]. Chitosan-coated liposomes have also demonstrated promising
antimicrobial effects in colistin-resistant Pseudomonas aeruginosa [80]. Sacco and colleagues
evaluated a physical chitosan hydrogel against S. epidermidis and revealed promising
antimicrobial activity [81]. These results along with other reports [82] demonstrate the
promising antimicrobial effects of chitosan-coated or infused vesicles in antimicrobial
treatment.
Since secondary vehicles are required in wound therapy, we aimed to investigate
whether chitosan hydrogel could further improve the effect of chitosan-infused vesicles
with CHX. Jøraholmen and colleagues compared the antimicrobial effects of both chitosan
hydrogel and chitosan-coated liposomes against both S. aureus and S. epidermidis and
reported promising effects of chitosan in low concentrations [14]. As seen in Table 5,
for S. aureus, almost all hydrogels exhibited a similar antimicrobial effect; only the CHX-
chitosomes-in-hydrogel showed slightly lowered MBC compared to the other hydrogel
formulations. However, the MBC for all hydrogels was lowered as compared to the
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vesicular suspensions. For S. epidermidis, the effects of different vesicles incorporated in the
hydrogel were more evident (Table 5). The activity increased upon the addition of CHX,
chitosan, and their combination. The most potent formulation was CHX-chitosomes-in-
hydrogel. Moreover, these results indicate that even a diluted hydrogel with a modified
chitosan network structure acts on improving the antimicrobial activity. The findings
confirmed that vesicle surface-available chitosan in combination with CHX induces the
strongest activity also when those vesicles were arranged within a chitosan network.
Table 5. MBC of vesicles in S. aureus and S. epidermidis.
Lipid Concentration (mg/mL) 4
S. aureus
Lipid Concentration (mg/mL) 4
S. epidermidis
Hydrogel 1.56 × 10−2 0.10 × 10−2
HG-PL-EMP 1.56 × 10−2 0.10 × 10−2
HG-CHI-EMP 1.56 × 10−2 0.025 × 10−2
HG-PL-CHX 1.56 × 10−2 0.0063 × 10−2
HG-CHI-CHX 0.78 × 10−2 0.0031 × 10−2
All results are expressed as the lipid concentration upon reaching MBC (n = 3). Hydrogel = plain hydrogel,
HG-PL-EMP = plain, empty vesicles-in-hydrogel, HG-CHI-EMP = empty chitosomes-in-hydrogel, HG-PL-CHX
= plain, CHX-vesicles-in-hydrogel, HG-CHI-CHX = CHX-chitosomes-in-hydrogel. 4 Lipid concentration or the
corresponding concentration of hydrogel.
3. Materials and Methods
3.1. Materials
Chitopharm™ M-Chitosan with medium molecular weight (average of 350–600 kDa)
and degree of deacetylation of >70% from shrimp was kindly provided by Chitinor (Tromsø,
Norway). Lipoid S100 was kindly provided by Lipoid GmbH (Ludwigshafen, Germany).
Methanol ≥ 99.9%, HiPerSolv CHROMANORM® for LC-MS and acetic acid (>99.9%) were
purchased from VWR International (Fontenay-sous-Bois, France). Cibacron Brilliant Red 3B-
A was procured from Santa Cruz Biotechnology (Dallas, TX, USA). Chlorhexidine > 99.5%,
glycerol solution (86–89%), glycine hydrochloride ≥ 99% (HPLC), sodium chloride, hy-
drochloric acid, Cell Counting Kit-8 (CCK-8), and Kollisolv® PEG E 400 were acquired from
Sigma-Aldrich (St. Louis, MO, USA). 1-Propanol, penicillin–streptomycin, and fetal bovine
serum (FBS) were purchased from Sigma-Aldrich (Steinheim, Germany). Blood agar plates,
saline solution, and Mueller–Hinton broth were delivered by University Hospital of North
Norway (Tromsø, Norway). Dulbecco’s Modified Eagle Medium high glucose (DMEM
HG) w/l-glutamine and sodium pyruvate was purchased from Biowest (Nuaillé, France).
HaCaT cell line (immortalized human keratinocytes) was purchased from CLS Cell Lines
Service GmbH (Eppelheim, Germany). Staphylococcus aureus (ATCC® BAA-1721™) MSSA
476 was purchased from LGC standards AB (Borås, Sweden). Staphylococcus epidermidis
(13–67) was delivered by University Hospital of Northern Norway (Tromsø, Norway).
3.2. Vesicle Preparation
3.2.1. Vesicle Preparation
The preparation of chitosomes was based on the one-pot method previously described
by Andersen et al. [31]. In short, Lipoid S100 (200 mg) and CHX (10 mg) were dissolved in
methanol and a lipid film was formed by evaporation of the solvent in a rotoevaporator
(Büchi rotavapor R-124, with vacuum controller B-721, Büchi vac V-500, Büchi Labortechnik,
Flawil, Switzerland) at 60 mBar and 45 ◦C for 1 h. A micro syringe (Innovative Labor Sys-
teme GmBH, Stutzerbach, Germany) filled with 150 µL 1-propanol was used to disperse the
lipid film. The 1-propanol/lipid dispersion was further injected into a chitosan dispersion
(0.17%, w/w, 2 mL) in acetic acid (0.1%, v/v) under continuous mechanical stirring. Finally,
the resulting suspension was stirred for another 2 h at room temperature (24 ± 1 ◦C) and
stored in the refrigerator (4 ◦C) prior to size reduction. Formulations without chitosan
were prepared in the same manner; however, the 1-propanol/lipid dispersion was injected
into distilled water (2 mL) instead of the chitosan dispersion. Formulations without CHX
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was prepared in the same way but without CHX. All vesicle designations and constituents
are included in Table 6.










Prior to size reduction, all vesicle suspensions were diluted with distilled water to
a lipid concentration of 20 mg/mL. The samples were probe sonicated (SONICS high-
intensity ultrasonic processor, 500-watt model, 13 mm probe diameter, Sonics & Materials
Inc., Newtown, CT, USA) at 40% amplitude for 10 s and ten times 10 s for the CHX-
containing and the empty vesicles, respectively. The sample containers were placed in an
ice bath throughout the sonication to avoid extensive heating.
3.3. Characterization of Chitosomes
3.3.1. Vesicle Size and Morphology
The size of vesicles was measured on a NICOMP Submicron particle sizer model
370 (NICOMP Particle Sizing system, Santa Barbara, CA, USA) described elsewhere [14].
The suspensions were diluted in filtered (0.2 µm) distilled water to reach an intensity
of 250–350 KHz and measured for three cycles of 10 min. The scattering angle of every
measurement was 90◦, and the temperature was 24 ± 1 ◦C. The results are expressed as the
weight-intensity distribution.
Prior to the morphological investigations, empty chitosomes and CHX-chitosomes
were deposited onto carbon-coated grids for 5 min, washed with double-distilled water,
and stained with 3% uranyl acetate and 2% methylcellulose (1:9) for 2 min. The samples
were picked up with a loop and dried on the loop holder. The images were obtained with a
transmission electron microscope HT7800 Series (Hitachi High-Tech Corp., Tokyo, Japan)
operating at an accelerated voltage of 100 kV coupled with a Morada camera.
3.3.2. Zeta Potential and pH of the Vesicles
The zeta potential was determined with a Malvern Zetasizer Nano Zen 2600 (Malvern,
Worcestershire, UK) as described earlier [83]. Zeta cells were rinsed three times with
methanol and filtered, deionized water prior to the measurements. The suspensions were
measured in three replicates at room temperature (24 ± 1 ◦C).
Determination of the pH was carried out with an Accumet®, Portable pH meter AP115
(Fischer Scientific, MA, USA) at room temperature (24 ± 1 ◦C).
3.3.3. Separation and Entrapment Efficiency
The free CHX was separated from the entrapped CHX by centrifugation [84]. The
chitosomes were centrifuged at 4000× g and 4 ◦C for 30 min on the Biofuge Stratos
centrifuge (Heraeus Instruments GmbH, Hanau, Germany). Entrapment analysis was
carried out on the SPARK® multimode microplate reader (Tecan Trading AG, Männedorf,
Switzerland) at 261 nm.
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3.3.4. Determination of Availability of Chitosan on the Surface
The determination of surface-available chitosan was based on a method described
by Muzzarelli [85]. Prior to the determination, the chitosomes were centrifuged in a cen-
trifugal filter (Amicon Ultra-2 Centrifugal Filter Unit Ultracel-10, Sigma-Aldrich, St. Louis,
MI, USA) at 3118× g for 15 min on the Biofuge Stratos centrifuge (Heraeus Instruments
GmbH, Hanau, Germany) [86]. First, glycine and NaCl was dissolved in distilled water in
concentrations of 0.748% (w/v) and 0.584% (w/v), respectively. A glycine buffer with pH
3.2 was prepared by diluting 81 mL of the glycine and NaCl solution with 0.1 M HCl to a
total volume of 100 mL. Next, a dye solution was prepared by dissolving Cibacron Brilliant
Red 3B-A (0.15%, w/v) in distilled water and 5 mL of this solution was diluted in glycine
buffer to a total volume of 100 mL. The centrifuged chitosomes were diluted (1:1, v/v) in
distilled water. An aliquot of 3 mL of the dye solution was added to 300 µL of the diluted
chitosomes, and the samples were analyzed on a UV-vis plate reader (Tecan Trading AG,
Männedorf, Switzerland) at 575 nm [87].
3.3.5. Chitosome and Vesicle Stability
The physical properties of chitosomes and plain vesicles (stored at 4 ◦C) were evalu-
ated after storage for two and four weeks after preparation. Properties evaluated were size,
PI, zeta potential, and pH as described in Sections 3.3.1 and 3.3.2.
3.4. Preparation and Characterization of Hydrogels
3.4.1. Preparation of Chitosan Hydrogel
Chitosan hydrogels comprising glycerol as a plasticizer were prepared in 2.5% (w/w)
acetic acid in distilled water. The dispersions were mixed with a Cito Unguator® 2000
(GAKO International AG, Zurich, Switzerland) and degassed by bath sonication (Bransonic®
5510R-MT Ultrasonic cleaner, Branson Ultrasonics Corporation, Danbury, CT, USA) for
30 min. The final concentrations of chitosan and glycerol were 4.5 and 9%, respectively.
Hydrogels were allowed to swell for 48 h prior to characterization or the incorporation of
vesicles.
The vesicles-in-hydrogel were prepared by incorporating 10% (w/w) vesicle suspen-
sion into chitosan hydrogels of 5% chitosan and 10% glycerol, respectively, by hand-stirring
for 5 min. The concentration of chitosan and glycerol after the incorporation of vesicular
suspensions were 4.5 and 9%, respectively. All hydrogel designations and their composition
are included in Table 7.



















Mar. Drugs 2021, 19, 269 16 of 21
3.4.2. Texture Properties and pH of Hydrogels
Texture properties of hydrogels were evaluated on the TA.XT plus Texture Analyser
(Stable Micro Systems Ltd., Surrey, UK) with a backward extrusion rig as previously
described by Hurler et al. [44]. The beaker of the rig set was filled with 65 g hydrogel and
the disc (35 mm) was compressed into the hydrogel and withdrawn back to the starting
position (above the surface). The measuring distance was 10 mm and the trigger force was
set to 10 g. The pre-test, test, and post-test speeds were 10, 4, and 4 mm/s, respectively.
Hardness, cohesiveness, and adhesiveness were recorded.
The pH of all hydrogels were measured with an Accumet®, Portable pH meter, AP115
(Fisher scientific, Waltham, MA, USA) at room temperature (24 ± 1 ◦C).
3.4.3. Viscosity Measurements
The measurements of viscosity were performed on a Rotavisc hi-vi II Complete
coupled with DINS-1 adapter with spindle DIN-SP-7 and DIN-C-2 chamber (IKA®-Werke
GmbH & Co. KG, Staufen, Germany). Both viscosity and shear stress was evaluated as a
function of the shear rate [51]. The shear rate range was between 4.0 s−1 and 23.63 s−1 and
the temperature was set to 25 or 32 ◦C.
3.5. CHX Release Studies
CHX release was determined in a Franz cell diffusion system (PermeGear, Hellertown,
PA, USA) with circulating heated water of 32 ◦C. The diffusion area of the pre-soaked
cellophane membrane (Max Bringmann KG, Wendelstein, Germany) was 1.77 cm2 and
the acceptor volume was 12 mL. Due to the lowered water solubility of CHX, the acceptor
chamber was filled with polyethylene glycol 400 (10%, v/v) in distilled water. The formu-
lations (600 µL) were added to the donor chamber. Samples were withdrawn from the
donor chamber after 24 h and analyzed as described in Section 3.3.3. The formulations
were compared with free CHX dissolved in the acceptor medium (permeation). The donor
chamber was weighed before and after every run to adjust for fluid exchange, and therefore,
the samples were measured only after 24 h [18].
3.6. Cell Viability Valuation
The cytotoxicity of formulations was evaluated using a Cell counting kit–8 (CCK-8,
Sigma-Aldrich Chemie, St. Louise, MI, USA) as described elsewhere [88]. Briefly, an
aliquot of 90 µL cell suspension cultured in DMEM HG supplemented with 10% (v/v)
FBS and 1% (v/v) penicillin–streptomycin (1 × 105 cells/mL) were plated on a 96-well
plate and incubated for 24 h at 37 ◦C with 5% CO2. Next, 10 µL of medium (control),
diluted vesicle suspension, or diluted hydrogel (1, 10, and 50 µg/mL lipid concentration
or the corresponding concentration of hydrogels) was added to the wells. The cells were
incubated for another 24 h at 37 ◦C with 5% CO2. After incubation, 10 µL CCK-8 was
added to each well, and the plates were incubated for 4 h. Finally, the plates were evaluated
at a UV-vis microplate reader (Tecan Trading AG, Männedorf, Switzerland) at 450 nm with
the reference set to 650 nm. All formulations were evaluated in triplicates and the results
were expressed as percentage compared to control.
3.7. Antimicrobial Evaluation
In the microbial evaluation, we sought to calculate the MBC for each formulation to
compare the effect of every modification for both vesicles and hydrogels. Here, we used
a modified broth micro-dilution method [89,90]. Two species were evaluated, namely S.
aureus MSSA 476 and S. epidermidis (13–67). Prior to the experiments, all hydrogels were
diluted 1:4 (v/v) in distilled water. All formulations were two-fold diluted in Mueller–
Hinton broth in sterile 96-well plates. Bacterial suspensions were prepared at 0.5 McFarland
in 0.85% (w/w) sodium chloride solutions, corresponding to approximately 108 CFU/mL.
The bacterial suspensions were further diluted (1:150, v/v) in Mueller–Hinton broth. The
inoculum was added to each well (1:1, v/v) in the 96-well plate and incubated at 37 ◦C on a
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shaker (100 rpm) for 24 h. The wells with only bacteria and Mueller–Hinton broth served as
positive and negative controls, respectively. After 24 h incubation, the bacterial suspensions
were 10-fold serial diluted in phosphate-buffered saline, plated on blood agar plates, and
incubated at 37 ◦C overnight [90]. The CFUs of the bacteria treated with formulations were
compared to the control (only growth medium) and the MBC (lipid concentration) was
determined.
3.8. Statistical Analyses
In general, results are expressed as mean ± SD. Student’s t-tests or one-way ANOVA
with Tukey post-test were performed to evaluate significance (p < 0.05). All statistical anal-
yses were performed in GraphPad Prism version 9.0.0 for Windows (GraphPad Software
LLC, San Diego, CA, USA).
4. Conclusions
Novel formulations for prevention and treatment of acute skin injuries prone to in-
fections are highly needed. This study supported the hypothesis that chitosan-infused
lipid-based vesicles, chitosomes loaded with CHX and incorporated into chitosan hydrogel
network could serve as a suitable formulation for infection control, prevention, and eradi-
cation of bacterial infections in acute wounds. The novel formulation displayed safety and
superior antimicrobial properties, which are both highly desirable for topical therapy of
infected wounds. Additionally, the combination of chitosan and CHX could provide both a
faster onset of the antimicrobial action and additionally offer a long-term effect on bacteria
in wounds.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
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of curcumin for multitargeted skin therapy. Eur. J. Pharm. Biopharm. 2019, 144, 154–164. [CrossRef] [PubMed]
